Xolair (omalizumab) - Roche, Novartis
Type I autoimmunity in chronic spontaneous urticaria: Evidence, limits, and endotype overlap. (PubMed, J Allergy Clin Immunol) - Oct 14, 2026 - "However, total IgE level, atopy, allergic disease, and timing of the response to omalizumab are not diagnostic of this mechanism...Progress will require harmonized functional assays; skin, mast cell, and basophil readouts, as well as longitudinal treatment studies. The central question is when an IgE autoantibody is only a passenger, when it is a partner, and when it is the driver of the wheal." 
Journal • Review • Allergy • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
http://www.ncbi.nlm.nih.gov/pubmed/42869400
 
Clive E H Grattan; George N Konstantinou
 
Oct 14, 2026
 
Prev Next